Loading company
$1.390.0%Nov 13 close
Figures through June 30, 2026, from the 10-Q filed August 14, 2026
Past performance
- 1W
- 0.0%
- 1M
- -16.5%
- 3M
- -87.4%
- 6M
- -92.9%
- 1Y
- -99.1%
$1.390.0%Nov 13 close
Figures through June 30, 2026, from the 10-Q filed August 14, 2026
The quarter ending September 30, 2020, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2020 | 3 months toSep 30, 2019 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $4.2K | -100.00% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Glucotrack, Inc. has no earnings call transcript available.
“During the quarter, we made meaningful progress advancing our CBGM program while further strengthening our foundation as a company,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes. Glucotrack’s Continuous Blood Glucose Monitor (CBGM) is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Glucotrack, Inc.’s Item 2.02 8-K filed May 14, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.